Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750903 | 1.00 | ACE (0.56) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL1543546 | 1.00 | ACE (0.56) | ACERENLMNACYP2C19HSD17B10 | |
| Bromide SCHEMBL6544002 | 0.98 | ACE (0.55) | ACERENLMNACYP2C19HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL29036064 | 0.98 | ACE (0.55) | ACERENLMNACYP2C19HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL29036066 | 0.98 | ACE (0.55) | ACERENLMNACYP2C19HSD17B10 | |
| Bicarbonate SCHEMBL7972998 | 0.96 | ACE (0.53) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL258790 | 0.93 | ACE (0.50) | ACEREN | |
| SCHEMBL6478173 | 0.93 | ACE (0.50) | ACEREN | |
| SCHEMBL1950731 | 0.93 | ACE (0.50) | ACEREN | |
| Bicarbonate SCHEMBL7973000 | 0.92 | ACE (0.50) | ACERENLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4365175-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | Spark Biopharma, Inc. (KR) | 2024-05-08 | — | — | EP | claimed |
| CN-117720413-A | 2, 4-dichlorophenoxyacetic acid eutectic and preparation method and application thereof | 天津大学 | 2024-03-19 | — | — | CN | claimed |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2021-05-13 | — | — | US | claimed |
| US-10874766-B2 | Compounds and matrices for use in bone growth and repair | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2020-12-29 | — | — | US | claimed |
| CN-106432713-B | Poly- (proline-sarcosine) material of Thermo-sensitive and preparation method thereof | 河北大学 | 2018-12-25 | — | — | CN | claimed |
| CN-108366998-A | PI3K inhibitor for treating cancers are used in preselected Patient with PIK3CA mutation in CTDNA | 诺华股份有限公司 | 2018-08-03 | — | — | CN | claimed |
| CN-108348520-A | MDM2 INHIBITORS AND COMBINATIONS THEREOF | 诺华股份有限公司 | 2018-07-31 | — | — | CN | claimed |
| CN-104661681-B | Pharmaceutical composition comprising inhibitors of phosphatidylinositol3 3-kinase and aromatase inhibitor | 诺华股份有限公司 | 2018-07-03 | — | — | CN | claimed |
| CN-105050623-B | Combination of PI3K inhibitor and C-MET inhibitor | 诺华股份有限公司 | 2018-06-12 | — | — | CN | claimed |
| CN-107106497-A | Pharmaceutical composition containing ALPELISI | 诺华股份有限公司 | 2017-08-29 | — | — | CN | claimed |
| EP-2847316-A1 | A BREWING METHOD | Novozymes A/S (DK) | 2015-03-18 | — | — | EP | claimed |
| CN-104271729-A | A brewing method | NOVOZYMES AS | 2015-01-07 | — | — | CN | claimed |
| CN-104271136-A | Pharmaceutical diagnostic | NOVARTIS AG | 2015-01-07 | — | — | CN | claimed |
| CN-104244949-A | Compounds for the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma | NOVARTIS AG | 2014-12-24 | — | — | CN | claimed |
| CN-103957909-A | 2-carboxamide cyclosemicarbazide derivatives for the treatment of VEGF-dependent diseases | NOVARTIS AG | 2014-07-30 | — | — | CN | claimed |
| CN-103889422-A | Method of treating gastrointestinal stromal tumors | NOVARTIS AG | 2014-06-25 | — | — | CN | claimed |
| CN-103857392-A | Combination of 2-carboxamide cycloamino urea derivatives with Hsp90 inhibitors for the treatment of proliferative diseases | NOVARTIS AG | 2014-06-11 | — | — | CN | claimed |
| WO-2013167573-A1 | A BREWING METHOD | NOVOZYMES A/S (DK) | 2013-11-14 | — | — | WO | claimed |
| CN-103200943-A | Use of 2-carboxamide cycloamino urea derivatives for the treatment of EGFR dependent diseases or diseases that are acquired tolerance to agents targeting EGFR family members | NOVARTIS AG | 2013-07-10 | — | — | CN | claimed |
| WO-2010011815-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874766-B2 | Compounds and matrices for use in bone growth and repair | BMP2, BMP4, BMP6 | ACE 4510/4885REN 4397/4885LMNA 1256/4885 |
| US-20210138117-A1 | COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR | BMP2, BMP4, BMP6 | ACE 4234/4885REN 4298/4885LMNA 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.